Interplay Between the Glymphatic System and Neurotoxic Proteins in Parkinson's Disease and Related Disorders: Current Knowledge and Future Directions

Overview

Journal Neural Regen Res

Date 2024 Jan 16

PMID 38227524

Authors

Yumei Yue

Xiaodan Zhang

Wen Lv

Hsin-Yi Lai

Ting Shen

Affiliations

Soon will be listed here.

Abstract

Parkinson's disease is a common neurodegenerative disorder that is associated with abnormal aggregation and accumulation of neurotoxic proteins, including α-synuclein, amyloid-β, and tau, in addition to the impaired elimination of these neurotoxic protein. Atypical parkinsonism, which has the same clinical presentation and neuropathology as Parkinson's disease, expands the disease landscape within the continuum of Parkinson's disease and related disorders. The glymphatic system is a waste clearance system in the brain, which is responsible for eliminating the neurotoxic proteins from the interstitial fluid. Impairment of the glymphatic system has been proposed as a significant contributor to the development and progression of neurodegenerative disease, as it exacerbates the aggregation of neurotoxic proteins and deteriorates neuronal damage. Therefore, impairment of the glymphatic system could be considered as the final common pathway to neurodegeneration. Previous evidence has provided initial insights into the potential effect of the impaired glymphatic system on Parkinson's disease and related disorders; however, many unanswered questions remain. This review aims to provide a comprehensive summary of the growing literature on the glymphatic system in Parkinson's disease and related disorders. The focus of this review is on identifying the manifestations and mechanisms of interplay between the glymphatic system and neurotoxic proteins, including loss of polarization of aquaporin-4 in astrocytic endfeet, sleep and circadian rhythms, neuroinflammation, astrogliosis, and gliosis. This review further delves into the underlying pathophysiology of the glymphatic system in Parkinson's disease and related disorders, and the potential implications of targeting the glymphatic system as a novel and promising therapeutic strategy.

Citing Articles

Relationships Between Glymphatic System Activity and Tau Burden, Dopaminergic Impairment, Abnormal Glucose Metabolism in Progressive Supranuclear Palsy.

Jiao F, Wang Q, Zhong J, Lin H, Lu J, Wang L CNS Neurosci Ther. 2025; 31(2):e70284.

PMID: 39963843 PMC: 11833299. DOI: 10.1111/cns.70284.

The cGAS-STING-interferon regulatory factor 7 pathway regulates neuroinflammation in Parkinson's disease.

Zhou S, Li T, Zhang W, Wu J, Hong H, Quan W Neural Regen Res. 2024; 20(8):2361-2372.

PMID: 39359093 PMC: 11759022. DOI: 10.4103/NRR.NRR-D-23-01684.

Relationship of Glymphatic Function with Cognitive Impairment, Sleep Disorders, Anxiety and Depression in Patients with Parkinson's Disease.

Gui Q, Meng J, Shen M, Feng H, Dong X, Xu D Neuropsychiatr Dis Treat. 2024; 20:1809-1821.

PMID: 39346025 PMC: 11439361. DOI: 10.2147/NDT.S480183.

Accumulation of Cerebrospinal Fluid, Ventricular Enlargement, and Cerebral Folate Metabolic Errors Unify a Diverse Group of Neuropsychiatric Conditions Affecting Adult Neocortical Functions.

Ikeda L, Capel A, Doddaballapur D, Miyan J Int J Mol Sci. 2024; 25(18).

PMID: 39337690 PMC: 11432090. DOI: 10.3390/ijms251810205.

References

Dickson D . Parkinson's disease and parkinsonism: neuropathology. Cold Spring Harb Perspect Med. 2012; 2(8). PMC: 3405828. DOI: 10.1101/cshperspect.a009258. View

Tu Y, Zhuo W, Peng J, Huang R, Li B, Liu Y . The correlation between enlarged perivascular spaces and cognitive impairment in Parkinson's disease and vascular parkinsonism. BMC Neurol. 2022; 22(1):282. PMC: 9336003. DOI: 10.1186/s12883-022-02819-7. View

Cho H, Choi J, Hwang M, Kim Y, Lee H, Lee H . In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum. Ann Neurol. 2016; 80(2):247-58. DOI: 10.1002/ana.24711. View

Chen H, Wan H, Zhang M, Wardlaw J, Feng T, Wang Y . Perivascular space in Parkinson's disease: Association with CSF amyloid/tau and cognitive decline. Parkinsonism Relat Disord. 2022; 95:70-76. DOI: 10.1016/j.parkreldis.2022.01.002. View

de Leon M, Li Y, Okamura N, Tsui W, Saint-Louis L, Glodzik L . Cerebrospinal Fluid Clearance in Alzheimer Disease Measured with Dynamic PET. J Nucl Med. 2017; 58(9):1471-1476. PMC: 5577629. DOI: 10.2967/jnumed.116.187211. View

Masliah E, Rockenstein E, Veinbergs I, Sagara Y, Mallory M, Hashimoto M . beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci U S A. 2001; 98(21):12245-50. PMC: 59799. DOI: 10.1073/pnas.211412398. View

Ding X, Wang X, Xia D, Liu H, Tian H, Fu Y . Impaired meningeal lymphatic drainage in patients with idiopathic Parkinson's disease. Nat Med. 2021; 27(3):411-418. DOI: 10.1038/s41591-020-01198-1. View

Galbiati A, Verga L, Giora E, Zucconi M, Ferini-Strambi L . The risk of neurodegeneration in REM sleep behavior disorder: A systematic review and meta-analysis of longitudinal studies. Sleep Med Rev. 2018; 43:37-46. DOI: 10.1016/j.smrv.2018.09.008. View

Hu W, Chen-Plotkin A, Arnold S, Grossman M, Clark C, Shaw L . Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease. Acta Neuropathol. 2010; 120(3):385-99. PMC: 2982700. DOI: 10.1007/s00401-010-0723-9. View

10.

Compta Y, Parkkinen L, Kempster P, Selikhova M, Lashley T, Holton J . The significance of α-synuclein, amyloid-β and tau pathologies in Parkinson's disease progression and related dementia. Neurodegener Dis. 2013; 13(2-3):154-6. PMC: 4194631. DOI: 10.1159/000354670. View

11.

Xu J, Liu Q, Huang S, Duan C, Lu H, Cao Y . The lymphatic system: a therapeutic target for central nervous system disorders. Neural Regen Res. 2022; 18(6):1249-1256. PMC: 9838139. DOI: 10.4103/1673-5374.355741. View

12.

Ramirez J, Berberian S, Breen D, Gao F, Ozzoude M, Adamo S . Small and Large Magnetic Resonance Imaging-Visible Perivascular Spaces in the Basal Ganglia of Parkinson's Disease Patients. Mov Disord. 2022; 37(6):1304-1309. DOI: 10.1002/mds.29010. View

13.

Chen H, Chen P, Lu C, Tsai N, Yu C, Chou K . Associations among Cognitive Functions, Plasma DNA, and Diffusion Tensor Image along the Perivascular Space (DTI-ALPS) in Patients with Parkinson's Disease. Oxid Med Cell Longev. 2021; 2021:4034509. PMC: 7904342. DOI: 10.1155/2021/4034509. View

14.

Semyachkina-Glushkovskaya O, Abdurashitov A, Dubrovsky A, Klimova M, Agranovich I, Terskov A . Photobiomodulation of lymphatic drainage and clearance: perspective strategy for augmentation of meningeal lymphatic functions. Biomed Opt Express. 2020; 11(2):725-734. PMC: 7041454. DOI: 10.1364/BOE.383390. View

15.

Ono K, Mochizuki H, Ikeda T, Nihira T, Takasaki J, Teplow D . Effect of melatonin on α-synuclein self-assembly and cytotoxicity. Neurobiol Aging. 2011; 33(9):2172-85. DOI: 10.1016/j.neurobiolaging.2011.10.015. View

16.

Cohen S, Linse S, Luheshi L, Hellstrand E, White D, Rajah L . Proliferation of amyloid-β42 aggregates occurs through a secondary nucleation mechanism. Proc Natl Acad Sci U S A. 2013; 110(24):9758-63. PMC: 3683769. DOI: 10.1073/pnas.1218402110. View

17.

Perosa V, Oltmer J, Munting L, Freeze W, Auger C, Scherlek A . Perivascular space dilation is associated with vascular amyloid-β accumulation in the overlying cortex. Acta Neuropathol. 2021; 143(3):331-348. PMC: 9047512. DOI: 10.1007/s00401-021-02393-1. View

18.

Hablitz L, Pla V, Giannetto M, Vinitsky H, Staeger F, Metcalfe T . Circadian control of brain glymphatic and lymphatic fluid flow. Nat Commun. 2020; 11(1):4411. PMC: 7468152. DOI: 10.1038/s41467-020-18115-2. View

19.

Si X, Guo T, Wang Z, Fang Y, Gu L, Cao L . Neuroimaging evidence of glymphatic system dysfunction in possible REM sleep behavior disorder and Parkinson's disease. NPJ Parkinsons Dis. 2022; 8(1):54. PMC: 9055043. DOI: 10.1038/s41531-022-00316-9. View

20.

Bae Y, Kim J, Choi B, Choi J, Ryoo N, Song Y . Glymphatic function assessment in Parkinson's disease using diffusion tensor image analysis along the perivascular space. Parkinsonism Relat Disord. 2023; 114:105767. DOI: 10.1016/j.parkreldis.2023.105767. View